Zacks Research Brokers Decrease Earnings Estimates for BIO

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Stock analysts at Zacks Research lowered their Q4 2025 earnings per share estimates for Bio-Rad Laboratories in a research note issued to investors on Wednesday, December 18th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $3.21 for the quarter, down from their previous forecast of $3.28. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.29 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2026 earnings at $3.16 EPS.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.85. The firm had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The firm’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same period in the prior year, the business posted $2.33 earnings per share.

Several other brokerages have also commented on BIO. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Wells Fargo & Company assumed coverage on Bio-Rad Laboratories in a report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price objective for the company. Royal Bank of Canada lifted their target price on Bio-Rad Laboratories from $369.00 to $481.00 and gave the company an “outperform” rating in a report on Monday, December 9th. Finally, Citigroup upped their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $394.20.

Bio-Rad Laboratories Trading Up 0.5 %

Shares of BIO stock opened at $327.47 on Monday. The firm’s 50-day simple moving average is $340.72 and its 200-day simple moving average is $322.62. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. Bio-Rad Laboratories has a 1-year low of $262.12 and a 1-year high of $387.99. The firm has a market cap of $9.17 billion, a P/E ratio of -11.98 and a beta of 0.90.

Hedge Funds Weigh In On Bio-Rad Laboratories

Several hedge funds and other institutional investors have recently made changes to their positions in BIO. Principal Financial Group Inc. raised its position in Bio-Rad Laboratories by 95.6% in the third quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock valued at $14,836,000 after purchasing an additional 21,669 shares during the period. Retirement Systems of Alabama grew its stake in shares of Bio-Rad Laboratories by 416.9% in the third quarter. Retirement Systems of Alabama now owns 23,260 shares of the medical research company’s stock valued at $7,782,000 after buying an additional 18,760 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its holdings in shares of Bio-Rad Laboratories by 17.0% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 28,523 shares of the medical research company’s stock valued at $9,543,000 after buying an additional 4,138 shares during the period. Neo Ivy Capital Management acquired a new position in Bio-Rad Laboratories during the 3rd quarter worth approximately $878,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Bio-Rad Laboratories in the 3rd quarter worth approximately $2,235,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.